The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $21.79 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%.  The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Segmentation & Regional Insights
The hepatitis therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

North America was the largest region in the hepatitis therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp

Major Driver Impacting Market Growth
The rise in hepatitis infection globally is expected to propel the growth of the hepatitis therapeutic market going forward. The rise in hepatitis infection is due to inadequate access to healthcare and vaccinations, an increase in intravenous drug use, unsafe blood transfusion practices, and poor sanitation and hygiene conditions in some parts of the world. For instance, in April 2022, according to World Health Organization (WHO), a US-based united nations public health agency, from 11 nations, at least 169 cases of acute hepatitis of unknown origin have been documented and 350 million individuals worldwide have viral hepatitis B or C, yet for the majority, testing, and treatment are still out of reach. Therefore, the market for hepatitis therapeutics is expanding due to the rise in hepatitis infection.

Key Industry Players
Major companies operating in the hepatitis therapeutics market are focusing on agreements to develop therapeutics to gain a competitive edge in the market. A strategic agreement is a formal contract between two or more parties that outlines the terms of their cooperation in achieving shared business goals. For instance, in October 2023, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced an agreement to obtain an exclusive license for JNJ-3989. It is an investigational subcutaneous RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B (CHB). JNJ-3989 is a novel RNAi therapeutic that targets the hepatitis B virus (HBV) X protein. The X protein is essential for HBV replication and viral persistence.

The hepatitis therapeutics market report table of contents includes:
1. Executive Summary
2. Hepatitis Therapeutics Market Characteristics
3. Hepatitis Therapeutics Market Trends And Strategies
4. Hepatitis Therapeutics Market - Macro Economic Scenario
5. Global Hepatitis Therapeutics Market Size and Growth
....................
31. Global Hepatitis Therapeutics Market Competitive Benchmarking
32. Global Hepatitis Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Hepatitis Therapeutics Market
34. Hepatitis Therapeutics Market Future Outlook and Potential Analysis
35. Appendix

Explore the trending research reports from TBRC:
https://goodprnews.com/human-computer-interaction-global-market-size/
https://goodprnews.com/internal-audit-management-software-global-market-size/
https://goodprnews.com/medical-software-global-market-size/
https://topprnews.com/human-computer-interaction-global-market-share/
https://topprnews.com/internal-audit-management-software-global-market-share/
https://topprnews.com/medical-software-global-market-share/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model